[肥胖患者胰岛素抵抗与脂质代谢紊乱之间的相互联系]
[Interconnection between insulin resistance and lipid metabolism disorders in obese patients].
作者信息
Ageeva V V, Krasil'nikova E I, Zubina I M, Shliakhto E V
出版信息
Ter Arkh. 2002;74(10):12-5.
AIM
Investigation of blood lipid spectrum, level of free fatty acids (FFA), glucose, insulin in blood and insulin resistance in obese patients depending on the type of obesity and effects on them of biguanides derivatives.
MATERIAL AND METHODS
Routine blood biochemical examination was made in 59 obese patients. 34 of them had trunk obesity (TO) and 25--gluteofemoral obesity (GFO). 18 patients with TO received gliformine treatment in a day dose 1.5 g for 3 months.
RESULTS
More pronounced metabolic disturbances indicated by the presence of insulin resistance, compensatory hyperinsulinemia, high levels of FFA associated with impaired glucose tolerance and dislipidemia, high rate of arterial hypertension were observed in patients with TO. Correlations were found between lipid metabolism disturbances and insulin resistance. Gliformin treatment resulted in loss of weight, decline of insulin resistance and hyperinsulinemia, improvement of carbohydrate metabolism, lipid blood spectrum, lowering of blood pressure.
CONCLUSION
Biguanide derivatives are a perspective group of drugs for treatment of the diseases running with insulin resistance.
目的
根据肥胖类型研究肥胖患者的血脂谱、游离脂肪酸（FFA）水平、血糖、血液中的胰岛素及胰岛素抵抗情况，以及双胍类衍生物对其的影响。
材料与方法
对59例肥胖患者进行常规血液生化检查。其中34例为躯干肥胖（TO），25例为臀股部肥胖（GFO）。18例TO患者接受格列吡嗪治疗，日剂量1.5 g，持续3个月。
结果
TO患者存在更明显的代谢紊乱，表现为胰岛素抵抗、代偿性高胰岛素血症、与糖耐量受损和血脂异常相关的高FFA水平、高动脉高血压发生率。发现脂质代谢紊乱与胰岛素抵抗之间存在相关性。格列吡嗪治疗导致体重减轻、胰岛素抵抗和高胰岛素血症下降、碳水化合物代谢改善、血脂谱改善、血压降低。
结论
双胍类衍生物是治疗伴有胰岛素抵抗疾病的有前景的药物组。
Zotero 插件